Skip to content
Combined Shape Created with Sketch.
  • COVID-19
  • EyewireTV
  • Stocks
  • Interests
    • Cataract and Refractive Eye-Grey Created with Sketch.
    • Glaucoma Gauge-Grey Created with Sketch.
    • Healthcare Cross-Grey Created with Sketch.
    • Optometry Laser-Grey Created with Sketch.
    • Product Approvals Gear-Grey Created with Sketch.
    • Retina Laser-Grey Created with Sketch.
  • More
    • Events
    • Subscribe
    • About
    • Send a Tip
    • Advertising
    • Privacy Policy
  • COVID-19
  • EyewireTV
  • Stocks
  • Interests
    • Cataract and Refractive Eye-Grey Created with Sketch.
    • Glaucoma Gauge-Grey Created with Sketch.
    • Healthcare Cross-Grey Created with Sketch.
    • Optometry Laser-Grey Created with Sketch.
    • Product Approvals Gear-Grey Created with Sketch.
    • Retina Laser-Grey Created with Sketch.
  • Events
  • About
  • Send a Tip
  • Advertising
  • Privacy Policy

Horizon Therapeutics

11.16.20

Horizon: New Data Build on Growing Evidence Supporting Tepezza Efficacy in Thyroid Eye Disease (TED)

Source: Horizon Therapeutics

11.11.20

New Data for Thyroid Eye Disease Treatment Tepezza to Be Presented at AAO Virtual

Source: Horizon Therapeutics

10.14.20

Tepezza Data From Phase 2 Clinical Trial Evaluate Longer-Term Responses in People Living with Thyroid Eye Disease (TED)

Source: Horizon Therapeutics

07.31.20

New Topline Tepezza Data Underscore its Efficacy in Potential for Retreatment in People Living with Thyroid Eye Disease (TED)

Source: Horizon Therapeutics

07.01.20

New Initiative Encourages the Graves’ Disease Community to FOCUS on Eye Health

Source: Horizon Therapeutics

05.14.20

New Data on the Pharmacokinetic Profile of Tepezza Reinforce the Labeled Dosing Regimen

Source: Horizon Therapeutics

05.11.20

US Physician Survey Illustrates the Impact of Thyroid Eye Disease on Patient Quality of Life

Source: Horizon Therapeutics

01.23.20

The New England Journal of Medicine Publishes Comprehensive Data from Phase 3 Clinical Trial of Tepezza for Thyroid Eye Disease

Source: Horizon Therapeutics

01.22.20

FDA Approves First Treatment for Thyroid Eye Disease

Source: FDA

12.16.19

FDA Advisory Committee Votes Unanimously to Support the Use of Teprotumumab for the Treatment of Thyroid Eye Disease (TED)

Source: Horizon Therapeutics

View more stories

Home

Menu

Share

  • Cataract and Refractive
  • Cornea
  • Glaucoma
  • Healthcare
  • Innovation
  • Optometry
  • Product Approvals
  • Retina
  • Events
  • About
  • Send a Tip
  • Advertising
  • Contact
  • EyewireTV
  • Stocks
  • Privacy Policy
Created with Sketch. Created with Sketch. Created with Sketch. Created with Sketch.
eyewire-news-color bmc-mark Created with Sketch.

© 2021 Bryn Mawr Communications, LLC.

All Rights Reserved.